Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol

By afschroeder • August 29, 2025

Holzgreve A, Delker A, Ells Z, Brosch-Lenz J, Unterrainer LM, Nikitas J, Zhu S, Contreras MM, Alam H, Nabong RM, Lira S, Vasilyev A, Chen L, Grogan T, Elashoff D, Meyer CA, Dahlbom M, Czernin J, Calais J. Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of ¹⁷⁷Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. J Nucl Med. 2025 Aug 28:jnumed.125.269495. doi: 10.2967/jnumed.125.269495. Epub ahead of print. PMID: 40876952.

Tags: [177Lu]Lu-PSMA-617, DOM STAT, General Internal Medicine, mCRPC, metastatic castration-resistant prostate cancer, Primary Care, prostate-specific membrane antigen, PSMA, Publications, radiopharmaceutical therapy, RPT, SPECT/CT, therapy response assessment, treatment holidays

Breaking the Chain of Survival: What Progetto Vita Tells Us, and What It Doesn’t

Talishinsky A, Ajijola OA, Salhi RA. Breaking the Chain of Survival: What Progetto Vita Tells Us, and What It Doesn't. J Am Heart Assoc. 2025[...]

Longitudinal Trajectories of Multimorbidity and Psychosocial Resilience Resources in Midlife and Older Adults: Findings From the Health and Retirement Study

White Whilby K, Robinson-Ector K, Bell BA, Ma T, Hasan S, Quiñones AR, Wei MY. Longitudinal Trajectories of Multimorbidity and Psychosocial Resilience Resources in Midlife[...]

Applying Race and Ethnicity in Health Disparities Research

Norris KC, Hudson MF, Wilson MR, Wojcik GL, Ofili EO, Hedges JR. Applying Race and Ethnicity in Health Disparities Research. Int J Environ Res Public[...]